Monoclonal antibodyFDA-approvedFirst-line
Cemiplimab
How it works
Blocks PD-1, a protein on immune cells that normally helps prevent overactive immune responses. By blocking PD-1, the immune system is less likely to suppress its own attack on cancer cells.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median overall survival of approximately 16.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combination Therapy Trial for Certain Cancers | Colorectal Cancer | phase-2 | — | Source → |
| Testing Fianlimab and Cemiplimab for Melanoma Prevention | Melanoma | phase-3 | — | Source → |
| Testing a Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Cemiplimab in High-Risk or Locally Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Cemiplimab Shows Promise in Treating Advanced Lung Cancer | Lung Cancer | meta-analysis | Significant survival benefits were observed in OS and PFS for patients receiving cemiplimab treatment, particularly those with PD-L1 expression levels ≥50%. | Source → |
| Testing Combination Therapy for Metastatic Colorectal Cancer with KRAS G12C Mutations | Colorectal Cancer | phase-1/2 | — | Source → |
| Combining a New Drug with Immunotherapy Shows Promise in Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 14.78% (90% CI, 5.30, 25.43). | Source → |
| Testing Immunotherapy in Advanced Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Testing a New Medicine for Advanced Prostate Cancer and Other Tumors | Prostate Cancer | phase-1 | — | Source → |
| Assessing Cemiplimab in Advanced Non-Small Cell Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Focused Ultrasound to Open Blood-Brain Barrier for Lung Cancer Brain Metastases | Lung Cancer | phase-3 | — | Source → |
| Cemiplimab Plus Chemotherapy Improves Survival in Advanced Lung Cancer | Lung Cancer | phase-3 | Median overall survival was 21.1 months for cemiplimab plus chemotherapy versus 12.9 months for chemotherapy alone. | Source → |
| Continuing Cemiplimab with Chemotherapy May Help Some Advanced Lung Cancer Patients | Lung Cancer | phase-3 | The objective response rate was 27.4%, and median overall survival from the time of randomization was 27.4 months. | Source → |
| Pegenzileukin and Cemiplimab Combination Shows Promise in Treating Advanced Skin Cancers | Melanoma | phase-1/2 | The objective response rate was 40% in Cohort A1 and 56.3% in Cohort B1. | Source → |
| Cemiplimab and Radioembolization for Liver Metastatic Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Cemiplimab and Chemotherapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Cemiplimab in Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Cemiplimab for Non-operative Management of Localized dMMR Colon Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing a New Medicine for Advanced Cancer | Melanoma | phase-1 | — | Source → |
| Testing Pidnarulex and Cemiplimab in Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing a New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Alirocumab and Cemiplimab Combination Tested in Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Cemiplimab-Based Therapy Linked to Better Survival in Lung Cancer Patients | Lung Cancer | phase-3 | Every 10-point improvement in global health status/quality of life was associated with a 31% reduction in the risk of death. | Source → |
| Evaluating Cemiplimab for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Cancer Treatment May Reactivate Hidden Leukemia | Leukemia | observational | — | Source → |
| Cemiplimab Improves Survival in Advanced Lung Cancer Patients | Lung Cancer | phase-3 | The overall survival was improved with cemiplimab monotherapy (median 26.1 versus 13.9 mo) and with cemiplimab plus chemotherapy (24.1 versus 13.8 mo) compared to chemotherapy alone. | Source → |
| Combining Fianlimab and Cemiplimab in Cancer Treatment | Lung Cancer | phase-1 | The objective response rate was 27% in NSCLC-N patients, 20% in ccRCC-N patients, 33% in HNSCC-N patients, and 20% in CSCC-E patients. | Source → |
| Cemiplimab Monotherapy vs. Chemotherapy in Advanced Lung Cancer | Lung Cancer | phase-3 | Statistically significant differences in the overall change from baseline in GHS/QoL favoring cemiplimab versus chemotherapy were observed overall and in multiple subgroups, including patients who had brain metastasis (p = .0110), an Eastern Cooperative Oncology Group performance status of 1 (p = .0017), squamous (p = .0247) and nonsquamous (p = .0073) histology, and patients aged 65 years and older (p = .0069). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.